# 18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

> **NCT06880328** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 35 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Ralmitaront
- **OTHER:** Radiolabeled PET tracer [18F]-DOPA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06880328
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-07
- **Primary completion:** 2019-09-04
- **Final completion:** 2019-09-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06880328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06880328, "18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06880328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*